PIK3CA mutations have been shown to be present in 3–5% of patients with pancreatic cancer.20, 21, 22, 23 Though this subtype does not represent the majority of pancreatic cancers, these patient's tumors might be exquisitely sensitive to treatments targeting the PI3K pathway. This evidence concerns the gene PIK3CA and familial pancreatic carcinoma.